Your browser doesn't support javascript.
loading
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
Bioorg Med Chem Lett ; 22(16): 5264-7, 2012 Aug 15.
Article in En | MEDLINE | ID: mdl-22795629
ABSTRACT
Calcium-dependent protein kinase-1 (CDPK1) from Cryptosporidium parvum (CpCDPK1) and Toxoplasma gondii (TgCDPK1) have become attractive targets for discovering selective inhibitors to combat infections caused by these protozoa. We used structure-based design to improve a series of benzoylbenzimidazole-based compounds in terms of solubility, selectivity, and potency against CpCDPK1 and TgCDPK1. The best inhibitors show inhibitory potencies below 50 nM and selectivity well above 200-fold over two human kinases with small gatekeeper residues.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Protein Kinases / Toxoplasma / Benzimidazoles / Protozoan Proteins / Cryptosporidium parvum / Protein Kinase Inhibitors Limits: Humans Language: En Year: 2012 Type: Article

Full text: 1 Database: MEDLINE Main subject: Protein Kinases / Toxoplasma / Benzimidazoles / Protozoan Proteins / Cryptosporidium parvum / Protein Kinase Inhibitors Limits: Humans Language: En Year: 2012 Type: Article